Journal of Clinical Oncology,
Journal Year:
2022,
Volume and Issue:
40(16), P. 1816 - 1837
Published: April 19, 2022
To
update
recommendations
on
appropriate
use
of
breast
cancer
biomarker
assay
results
to
guide
adjuvant
endocrine
and
chemotherapy
decisions
in
early-stage
cancer.An
updated
literature
search
identified
randomized
clinical
trials
prospective-retrospective
studies
published
from
January
2016
October
2021.
Outcomes
interest
included
overall
survival
disease-free
or
recurrence-free
survival.
Expert
Panel
members
used
informal
consensus
develop
evidence-based
recommendations.The
24
informing
the
evidence
base.Clinicians
may
Oncotype
DX,
MammaPrint,
Breast
Cancer
Index
(BCI),
EndoPredict
patients
who
are
postmenopausal
age
>
50
years
with
estrogen
receptor
(ER)-positive,
human
epidermal
growth
factor
2
(HER2)-negative
(ER+
HER2-)
that
is
node-negative
1-3
positive
nodes.
Prosigna
BCI
be
ER+
HER2-
cancer.
In
premenopausal
patients,
clinicians
Current
data
suggest
nodes
benefit
regardless
genomic
result.
There
no
tests
≥
4
Ki67
combined
other
parameters
immunohistochemistry
score
without
access
therapy
decisions.
offered
0-3
received
5
recurrence
about
extended
therapy.
None
assays
recommended
for
treatment
guidance
individuals
HER2-positive
triple-negative
Treatment
should
also
consider
disease
stage,
comorbidities,
patient
preferences.Additional
information
available
at
www.asco.org/breast-cancer-guidelines.
Annals of Oncology,
Journal Year:
2016,
Volume and Issue:
28(1), P. 16 - 33
Published: Oct. 11, 2016
Advanced
Breast
Cancer
(ABC)
comprises
both
locally
advanced
(LABC)
and
metastatic
breast
cancer
(MBC)
[1].
Although
treatable,
MBC
remains
an
incurable
disease
with
a
median
overall
survival
of
∼2–3
years
5-year
only
∼25%
[2–4].
Some
more
recent
series
seem
to
indicate
improvement
in
[5,
6].
Annals of Oncology,
Journal Year:
2020,
Volume and Issue:
31(6), P. 745 - 759
Published: March 30, 2020
Early
cancer
detection
could
identify
tumors
at
a
time
when
outcomes
are
superior
and
treatment
is
less
morbid.
This
prospective
case-control
sub-study
(from
NCT02889978
NCT03085888)
assessed
the
performance
of
targeted
methylation
analysis
circulating
cell-free
DNA
(cfDNA)
to
detect
localize
multiple
types
across
all
stages
high
specificity.
Journal of the National Comprehensive Cancer Network,
Journal Year:
2022,
Volume and Issue:
20(5), P. 497 - 530
Published: May 1, 2022
NCCN
Clinical
Practice
Guidelines
in
Oncology
(NCCN
Guidelines)
for
Non-Small
Cell
Lung
Cancer
(NSCLC)
provide
recommended
management
patients
with
NSCLC,
including
diagnosis,
primary
treatment,
surveillance
relapse,
and
subsequent
treatment.
Patients
metastatic
lung
cancer
who
are
eligible
targeted
therapies
or
immunotherapies
now
surviving
longer.
This
selection
from
the
NSCLC
focuses
on
actionable
mutations.
New England Journal of Medicine,
Journal Year:
2020,
Volume and Issue:
383(10), P. 931 - 943
Published: May 28, 2020
A
splice-site
mutation
that
results
in
a
loss
of
transcription
exon
14
the
oncogenic
driver
MET
occurs
3
to
4%
patients
with
non-small-cell
lung
cancer
(NSCLC).
We
evaluated
efficacy
and
safety
tepotinib,
highly
selective
inhibitor,
this
patient
population.
In
open-label,
phase
2
study,
we
administered
tepotinib
(at
dose
500
mg)
once
daily
advanced
or
metastatic
NSCLC
confirmed
skipping
mutation.
The
primary
end
point
was
objective
response
by
independent
review
among
who
had
undergone
at
least
9
months
follow-up.
also
analyzed
according
whether
presence
detected
on
liquid
biopsy
tissue
biopsy.
As
January
1,
2020,
total
152
received
99
been
followed
for
months.
rate
46%
(95%
confidence
interval
[CI],
36
57),
median
duration
11.1
CI,
7.2
could
not
be
estimated)
combined-biopsy
group.
48%
61)
66
liquid-biopsy
group
50%
37
63)
60
tissue-biopsy
group;
27
positive
both
methods.
investigator-assessed
56%
45
66)
similar
regardless
previous
therapy
disease.
Adverse
events
grade
higher
were
considered
investigators
related
reported
28%
patients,
including
peripheral
edema
7%.
led
permanent
discontinuation
11%
patients.
molecular
response,
as
measured
circulating
free
DNA,
observed
67%
matched
samples
baseline
during
treatment.
Among
mutation,
use
associated
partial
approximately
half
Peripheral
main
toxic
effect
higher.
(Funded
Merck
[Darmstadt,
Germany];
VISION
ClinicalTrials.gov
number,
NCT02864992.).
